Characteristics of CD44 alternative splice pattern in the course of human colorectal adenocarcinoma progression

• Published in: Molecular cancer 2012-11, Vol.11 (1), p.83-83
• Main Authors: Bánky, Balázs, Rásó-Barnett, Lívia, Barbai, Tamás, Tímár, József, Becságh, Péter, Rásó, Erzsébet
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Adenocarcinoma - genetics; Adenocarcinoma - metabolism; Adenocarcinoma - pathology; Alternative; Alternative Splicing; Animals; Binding sites; Cancer; CD44; Cell adhesion & migration; Cell Line, Tumor; Colorectal; Colorectal cancer; Colorectal Neoplasms - genetics; Colorectal Neoplasms - metabolism; Colorectal Neoplasms - pathology; Comparative analysis; Computers; Development and progression; Exons; HCT116 Cells; HT29 Cells; Humans; Hyaluronan Receptors - genetics; Hyaluronan Receptors - metabolism; Lung Neoplasms - genetics; Lung Neoplasms - secondary; Metastasis; Mice; Microenvironment; Protein Isoforms; Protein Stability; Proteins; Services; Signal transduction; Splicing; Transplantation, Heterologous
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/1476-4598-11-83

CD44 is considered as 'a' metastasis associated gene, despite the fact that it is an umbrella term for a group of molecules produced from a single gene by alternative splicing. However, little consideration is given to the above in the literature of colorectal carcinomas as well as other tumour types, leading to confusion and contradictory results about its possible role in tumour progression. We compared the CD44 alternative splice pattern (ASP) of three genetically different human colorectal cancer cell lines (HT25, HT29, HCT116) using a series of PCR reactions and next- generation sequencing method, as well as identified a colorectal adenocarcinoma specific CD44 ASP. This ASP was further investigated in terms of its qualitative and quantitative stability in our experimental iso- and xenograft mouse models for colorectal cancer progression. A complex preclinical experimental set-up was established to separately test the different steps of tumour progression and the role of tumour microenvironment, respectively, focusing on the role of 'CD44' in this process. We managed to present a colorectal cancer-specific CD44 ASP, which remained unchanged from cell lines throughout primary tumour formation and metastatic progression. Furthermore, we report a unique roster of all expressed CD44 variant isoforms characteristic to colorectal cancer. Finally, on quantitative assessment of the variable exons v3 and v6, higher co-expression levels were found to be characteristic to metastatically potent tumour cells. Particular CD44 variant isoforms seem to act as "metastasis genes" via tumour microenvironment-driven shifts in v3 and v6 expressions. However, this function may just affect a minority of tumour subclones. This fact and the huge potential number of different CD44 splice variants that can contain v3 and v6 domains can explain incoherence of clinical studies regarding functional asessment of CD44 variants, as well as diminish the chances of using CD44 variants for predictive purpose.